Gamida Cell: Delaware Enforces Israeli Debt Arrangement on $75M Highbridge Swap
ElevenFlo ·
Gamida Cell Ltd.’s Chapter 15 case was closed by an order entered on May 24, 2024, after a notice reported effectiveness and full administration. The closing order Dkt. 53 is the latest identified case disposition; no further milestone is established in the case materials.
Jump to section
Gamida Cell Ltd.'s chapter 15 case produced what its advisers described as the first U.S. recognition and enforcement blankrome.com: Blank Rome Advises Gamida Cell on Global Restructuring (Blank Rome, 2024-07) (outside source) of an Israeli debt arrangement, a cross-border structure that converted $75 million of Highbridge debt into equity globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source) and took the Israeli cell-therapy company private. The arrangement became effective on May 24, 2024 sec.gov: Gamida Cell Chapter 11 SEC Filing (SEC, 2024-05) (outside source), nine days after the Delaware court recognized the foreign proceeding.
Gamida filed its chapter 15 petition Dkt. 1 on April 22, 2024 in the U.S. Bankruptcy Court for the District of Delaware, lead case number 24-10847, to obtain recognition of a debt arrangement pending before the District Court in Be'er-Sheva, Israel. The substantive reorganization ran through the Israeli court under Part 10 of the country's insolvency law, while Delaware's role was to extend the automatic stay to U.S. assets and enforce the Israeli confirmation order against U.S. creditors. The verified petition Dkt. 4 and the supporting declaration of CEO Abigail Jenkins Dkt. 5 set out the company's capital structure, the causes of distress, and the basis for treating Israel as the center of main interests.
| Debtor | Gamida Cell Ltd. |
| Court | U.S. Bankruptcy Court, District of Delaware |
| Case Number | 24-10847 |
| Judge | Hon. J. Kate Stickles |
| Petition Date | April 22, 2024 |
| Recognition & Enforcement | May 15, 2024 |
| Effective Date | May 24, 2024 |
| Foreign Proceeding | Israeli debt arrangement under Part 10 of the Insolvency and Economic Rehabilitation Law (Be'er-Sheva District Court, Case No. 63461-03-24) |
| Debt Converted | $75 million senior notes converted to 100% of reorganized equity |
| Exit Financing | $49.4 million from Highbridge |
| Shareholder Consideration | Contingent value rights up to $27.5 million |
Table: Case Snapshot
Highbridge Debt-for-Equity Swap and CVR Structure
The restructuring was anchored by a restructuring support agreement executed March 26, 2024 globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source) among Gamida Cell Ltd., its U.S. subsidiary Gamida Cell Inc., and Highbridge Capital Management. Under the RSA, Highbridge agreed to convert its $75 million of senior notes into all of the reorganized equity Dkt. 4, cancel existing shares, and support delisting from Nasdaq. The Jenkins declaration Dkt. 5 states the board concluded that the Highbridge proposal was the only realistic alternative to an Israeli liquidation proceeding and wind-down.
In exchange for their cancelled shares, existing shareholders received contingent value rights of up to $27.5 million globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source) payable on future milestones. Non-Highbridge general unsecured creditors were left unimpaired and paid in the ordinary course, a structure the verified petition Dkt. 4 presented as preserving going-concern value and paying ordinary creditors in full while handing Highbridge full ownership in return for deleveraging and new capital. The Jenkins declaration Dkt. 5 states the arrangement had to be approved and become effective on or before May 15, 2024, or the company would likely default, lose the ability to pay general unsecured creditors in full, and face liquidation with liabilities exceeding assets.
Cash Burn and the Failed Strategic Review
The filing followed a multi-year effort to fund commercialization. Gamida was founded in Jerusalem in 1998 finder.startupnationcentral.org: Gamida Cell - Israeli Startup Profile (Startup Nation Finder, 2024) (outside source) and built a nicotinamide-based platform to expand stem cells and natural killer cells, going public on Nasdaq in 2018 globalventuring.com: Gamida Cell IPO (Global Venturing, 2018-10) (outside source). Omisirge (omidubicel-onlv) received FDA approval on April 17, 2023 Dkt. 4 as the first FDA-approved expanded cord blood product, but the Jenkins declaration Dkt. 5 records only about $1.78 million of revenue in 2023 against an addressable market of fewer than 10,000 stem-cell transplants annually and a net selling price near $300,000 per patient.
Management ran a strategic process beginning when Moelis moelis.com: Gamida Cell Ltd.'s debt-for-equity exchange with ... (outside source) pursued royalty financing and licensing in July 2020. The Jenkins declaration Dkt. 5 states the company approached more than 75 strategic investors and 11 royalty investors, and that later review of asset-sale, merger, licensing, distribution, and restructuring alternatives did not yield actionable third-party transactions globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source).
By early 2024 the company was burning about $7 million per month stocktitan.net: Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results (Stock Titan, 2024-03) (outside source) and was nearing the minimum-liquidity covenant under its Highbridge debt. The Jenkins declaration Dkt. 5 ties the collapse to a 2022 FDA timing setback, a smaller-than-planned 2022 capital raise, a 2023 workforce reduction, and a declining share price that left any near-term equity raise both highly dilutive and too small to close the liquidity gap.
Delaware Recognition, COMI, and Enforcement
The verified petition Dkt. 4 argued that Israel was Gamida's center of main interests, citing Israeli incorporation and registered office, the Kiryat Gat manufacturing and R&D base, the location of most employees and books and records, and the Innovation Authority grants restricting transfer of know-how. As of March 15, 2024 the company had 143 full-time employees, 99 of them based in Israel.
On May 15, 2024, Judge J. Kate Stickles entered a final order recognizing Dkt. 46 the Israeli case as a foreign main proceeding, granting section 1520 relief including the automatic stay and additional section 1521 relief enjoining U.S. actions against the debtor and its assets. The order treated the Israeli court's process as the basis for comity and enforcement in the United States.
A separate enforcement order Dkt. 47 gave the Israeli confirmation order and debt arrangement full force in the United States, permanently enjoined actions inconsistent with the restructuring, approved the conversion of the 2026 senior notes into all of the reorganized equity, and held the CVRs exempt from registration under section 1145. The motion to recognize and enforce Dkt. 7 had set out the legal basis for that relief.
The cross-border structure paired the parent's chapter 15 recognition with a short chapter 11 case for the U.S. subsidiary, Gamida Cell Inc. Law-firm summaries described the coordinated chapter 15 and chapter 11 approach cooley.com: Gamida Cell Completes International Restructuring (Cooley, 2024-06-21) (outside source) as a framework for Israeli companies that need U.S. recognition and enforcement of a restructuring governed by Israeli law.
Effective Date, Delisting, and Workforce Reduction
The notice of effective date Dkt. 51 filed May 24, 2024 stated that the debt arrangement had become effective, and the court entered the order closing the chapter 15 case Dkt. 53 the same day after finding it fully administered. The case closed nine days after the Delaware recognition and enforcement orders.
Highbridge became the sole equity owner through Ayrmid Limited, a vehicle it established for the purpose, and the company delisted from Nasdaq en.globes.co.il: Gamida Cell to delist as Highbridge takes full ownership (Globes, 2024-05) (outside source), taking Gamida Cell private. Israeli coverage reported a 25% workforce reduction en.globes.co.il: Gamida Cell to delist as Highbridge takes full ownership (Globes, 2024-05) (outside source) and closure of the Jerusalem development center, while the Kiryat Gat production site continued operating.
The financing package totaled $49.4 million Dkt. 5, composed of about $30 million of new senior secured term loans, a roll-up of the roughly $4.4 million of secured notes outstanding, and up to $15 million of delayed-draw commitments. Highbridge structured the capital to fund continued commercialization of Omisirge biospace.com: BioSpace - Gamida Restructures Under Ownership of Highbridge (2024-06) (outside source) under the new ownership.
In June 2024, Gamida Cell announced new executive leadership businesswire.com: Business Wire - Gamida Announces New Leadership Under Ownership of Highbridge Capital Management (2024-06-18) (outside source) under Ayrmid to oversee continued commercialization. By November 2024, Ayrmid entered an exclusive license agreement with BioLineRx Ltd. ir.biolinerx.com: BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. (BioLineRx IR, 2024-11-20) (outside source) for APHEXDA (motixafortide), a stem cell mobilization agent for multiple myeloma patients, with a $10 million upfront payment, up to $87 million in commercial milestones, and royalties of 18% to 23%; Highbridge simultaneously made a $9 million equity investment in BioLineRx. In December 2025, Omisirge received a second FDA approval fiercepharma.com: Fierce Pharma - Gamida Cell Scores 2nd FDA Nod for Omisirge (2025-12-09) (outside source), this time for severe aplastic anemia, under Ayrmid's ownership.
Key Timeline
| Date | Event |
|---|---|
| March 26, 2024 | RSA executed globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source) among Gamida, Gamida Cell Inc., and Highbridge |
| March 27, 2024 | Israeli Part 10 debt arrangement commenced in Be'er-Sheva |
| April 4, 2024 | Israeli preliminary hearing sets objection and proof-of-debt deadlines; merits hearing set for May 5 |
| April 9, 2024 | Israeli court appoints Ram Levy, CPA, as valuation expert |
| April 18, 2024 | Two shareholder objections filed in Israel |
| April 22, 2024 | Chapter 15 petition and supporting declarations filed in Delaware |
| April 23, 2024 | Delaware scheduling order entered for the recognition hearing |
| May 5, 2024 | Israeli approval hearing; expert recommends improved CVR terms |
| May 15, 2024 | Delaware recognizes the foreign main proceeding and enforces the arrangement |
| May 24, 2024 | Effective date; chapter 15 case closed |
Frequently Asked Questions
What does Gamida Cell Ltd. do?
Gamida Cell develops cell therapy products using a nicotinamide-based platform to expand stem cells and natural killer cells. Its lead product, Omisirge (omidubicel-onlv), received FDA approval in April 2023 as the first FDA-approved expanded cord blood product for transplant patients.
Why did Gamida Cell file chapter 15?
The parent company restructured through an Israeli debt arrangement, and chapter 15 in Delaware was used to recognize and enforce that proceeding in the United States, extend the automatic stay to U.S. assets, and protect the note-to-equity conversion against U.S. creditor actions. The motion to recognize and enforce Dkt. 7 outlines the legal basis for the cross-border approach.
What were the headline terms of the Israeli debt arrangement?
Highbridge agreed to convert about $75 million of senior notes into equity globenewswire.com: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27) (outside source), taking 100% ownership. Existing equity was cancelled and replaced with contingent value rights of up to $27.5 million, while other unsecured creditors were left unimpaired and paid in the ordinary course.
What exit financing supported the restructuring?
Highbridge provided a $49.4 million financing package Dkt. 5, including roughly $30 million of new senior secured term loans, a roll-up of about $4.4 million of secured debt outstanding, and up to $15 million of delayed-draw commitments.
When was the chapter 15 case filed and when did it end?
The chapter 15 petition Dkt. 1 was filed on April 22, 2024. The arrangement became effective on May 24, 2024, and the court entered the order closing the case Dkt. 53 the same day.
Who is the noticing agent for the Gamida Cell chapter 15 case?
Kroll Restructuring Administration LLC serves as the noticing agent. The Delaware scheduling order Dkt. 22 identifies Kroll's role in distributing notice and maintaining the public case website.
ElevenFlo covers Gamida Cell's parallel chapter 11 prepack separately, along with comparable cross-border proceedings including Casino's chapter 15 recognition of a French restructuring, Afiniti's chapter 15 of a Bermuda restructuring, and Altice France's chapter 15 of a French restructuring.
Sources
- Dkt. 1Chapter 15 Petition for Recognition of Foreign Proceeding. Fee Amount $1738 Filed by Abigail L. Jenkins, Gamida Cell Ltd..Filed Apr 22, 2024Apr 22, 2024
- Dkt. 4Exhibit(s) // Verified Petition Under Chapter 15 for Recognition of the Israeli Proceeding as a Foreign Main Proceeding or, Alternatively, a Foreign Nonmain Proceeding (related document(s)1) Filed by Abigail L. Jenkins. (Attachments: # 1 Declaration of Abigail Jenkins in Support of Verified Petition # 2 Exhibit A)Filed Apr 22, 2024Apr 22, 2024
- Dkt. 5Declaration of Abigail Jenkins in Support of the (I) Verified Petition Under Chapter 15 for Recognition of the Israeli Proceeding as a Foreign Main Proceeding or, Alternatively, a Foreign Nonmain Proceeding, and (II) Motion Seeking Recognition and Enforcement of the Debt Arrangement and Israeli Confirmation Order (related document(s)4) Filed by Abigail L. Jenkins. (Attachments: # 1 Exhibit A # 2 Exhibit B)Filed Apr 22, 2024Apr 22, 2024
- Dkt. 6Declaration of Pinni Yaniv in Support of the (I) Verified Petition and (II) Motion for Recognition and Enforcement of the Debt Arrangement and Israeli Confirmation Order (related document(s)4) Filed by Abigail L. Jenkins. (Attachments: # 1 Exhibit A # 2 Exhibit B # 3 Exhibit C # 4 Exhibit D # 5 Exhibit E # 6 Exhibit F # 7 Exhibit G # 8 Exhibit H)Filed Apr 22, 2024Apr 22, 2024
- Dkt. 7Motion to Approve // Motion for Order (I) Recognizing and Enforcing the Debt Arrangement and Israeli Confirmation Order Pursuant to 11 U.S.C. §§ 105(a), 1145, 1507(a), 1521, and 1525(a), (II) Approving the Procedure Governing the Closing of This Chapter 15 Case, and (III) Granting Related Relief Filed by Abigail L. Jenkins. (Attachments: # 1 Exhibit A # 2 Exhibit B)Filed Apr 22, 2024Apr 22, 2024
- Dkt. 22ORDER (A) SCHEDULINGHEARING ON RECOGNITION OF CHAPTER 15 PETITION AND(B) SPECIFYING FORM AND MANNER OF SERVICE OF NOTICE (Related Doc # 8)(related document(s)21) Order Signed on 4/23/2024. (Attachments: # 1 Exhibit 1)Filed Apr 23, 2024Apr 23, 2024
- Dkt. 37Supplemental Declaration in Support // Supplemental Declaration of Pinni Yaniv in Support of the (I) Verified Petition and (II) Motion for Recognition and Enforcement of the Debt Arrangement and Israeli Confirmation Order (related document(s)4, 7) Filed by Abigail L. Jenkins.Filed May 9, 2024May 9, 2024
- Dkt. 46FINAL ORDER GRANTING RECOGNITION ANDRELIEF IN AID OF A FOREIGN MAIN PROCEEDING (related document(s)4, 5, 6, 22, 28, 37, 38, 39) Order Signed on 5/15/2024.Filed May 15, 2024May 15, 2024
- Dkt. 47FINAL ORDER GRANTING MOTION(I) RECOGNIZING AND ENFORCING THE DEBT ARRANGEMENTAND ISRAELI CONFIRMATION ORDER PURSUANT TO 11 U.S.C.§§ 105(a), 1145, 1507(a), 1521, AND 1525(A), AND (II) GRANTING RELATED RELIEF(Related Doc # 7)(related document(s)5, 6, 22, 29, 37, 38, 40) Order Signed on 5/15/2024.Filed May 15, 2024May 15, 2024
- Dkt. 51Notice of Effective Date and Full Administration (related document(s)7, 47) Filed by Abigail L. Jenkins.Filed May 24, 2024May 24, 2024
- Dkt. 53Order Closing Chapter 15 Case (related document(s)52) Order Signed on 5/24/2024.Filed May 24, 2024May 24, 2024
- WebBlank Rome Advises Gamida Cell on Global Restructuring (Blank Rome, 2024-07)blankrome.com · Outside source
- WebGamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management (GlobeNewswire, 2024-03-27)globenewswire.com · Outside source
- WebGamida Cell Chapter 11 SEC Filing (SEC, 2024-05)sec.gov · Outside source
- WebGamida Cell - Israeli Startup Profile (Startup Nation Finder, 2024)finder.startupnationcentral.org · Outside source
- WebGamida Cell IPO (Global Venturing, 2018-10)globalventuring.com · Outside source
- WebGamida Cell Ltd.'s debt-for-equity exchange with ...moelis.com · Outside source
- WebGamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results (Stock Titan, 2024-03)stocktitan.net · Outside source
- WebGamida Cell Completes International Restructuring (Cooley, 2024-06-21)cooley.com · Outside source
- WebGamida Cell to delist as Highbridge takes full ownership (Globes, 2024-05)en.globes.co.il · Outside source
- WebBioSpace - Gamida Restructures Under Ownership of Highbridge (2024-06)biospace.com · Outside source
- WebBusiness Wire - Gamida Announces New Leadership Under Ownership of Highbridge Capital Management (2024-06-18)businesswire.com · Outside source
- WebBioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. (BioLineRx IR, 2024-11-20)ir.biolinerx.com · Outside source
- WebFierce Pharma - Gamida Cell Scores 2nd FDA Nod for Omisirge (2025-12-09)fiercepharma.com · Outside source